ライフサイエンスコーパス: patent ductus arteriosus

1 s of death or bronchopulmonary dysplasia and patent ductus arteriosus.

2 encodes a Notch ligand, die postnatally from patent ductus arteriosus.

3 the use of indomethacin to treat symptomatic patent ductus arteriosus.

4 treatment, despite success in closure of the patent ductus arteriosus.

5 anomalous lobar pulmonary veins or a silent patent ductus arteriosus.

6 those neonates without clinically suspected patent ductus arteriosus.

7 y be of predictive value for the presence of patent ductus arteriosus.

8 uctus arteriosus, with a 92% specificity for patent ductus arteriosus.

9 established techniques for coil occlusion of patent ductus arteriosus.

10 ductal shunting following coil occlusion of patent ductus arteriosus.

11 red with those of 14 preterm infants without patent ductus arteriosus.

12 7, 47%), atrial septal defects (20/47, 43%), patent ductus arteriosus (16/47, 34%), persistent left s

13 al CHD, 4 with atrial septal defects, 2 with patent ductus arteriosus, 2 with tetralogy of Fallot, an

14 In other areas, such as patent ductus arteriosus and atrioventricular septal def

15 ent with epilepsy and other signs, including patent ductus arteriosus and coagulopathy, while hemizyg

16 Patent ductus arteriosus and coarctation of aorta occurr

17 11 (c.4599+1delG) was identified in familial patent ductus arteriosus and found to disrupt normal spl

18 us arteriosus to close after birth is termed patent ductus arteriosus and is one of the most common c

19 f particular interest because it also causes patent ductus arteriosus and moyamoya disease.

20 studies describing an association between a patent ductus arteriosus and the development of morbidit

21 A concomitant cardiac lesion, for example, patent ductus arteriosus, and aortic cross-clamp time we

22 of patients with interatrial communications, patent ductus arteriosus, and pulmonary artery stenosis

23 fied young age at angioplasty, presence of a patent ductus arteriosus, and the diameters of the aorti

24 ds ratio [AOR], 0.81; 95% CI, 0.67-0.98) and patent ductus arteriosus (AOR, 0.74; 95% CI, 0.62-0.89).

25 tal defect (aORs ranging from 1.29 to 2.17), patent ductus arteriosus [aORs = 1.54, 1.63; 95% confide

26 hose neonates subsequently diagnosed to have patent ductus arteriosus, based on clinical suspicion an

27 premature infants with than in those without patent ductus arteriosus because afterload is lower in t

28 atrial and atrioventricular septal defects, patent ductus arteriosus, bicuspid aortic valve, and coa

29 tif mutation, P62R, had a high prevalence of patent ductus arteriosus but had only mild abnormalities

30 shunts are common after coil embolization of patent ductus arteriosus, but most close spontaneously.

31 disruption of this pathway may contribute to patent ductus arteriosus by affecting the development of

32 facial dysmorphology, osteochondrodysplasia, patent ductus arteriosus, cardiomegaly, pericardial effu

33 ulmonary artery diameter Z score <or=-2.5 or patent ductus arteriosus diameter <or=2 mm was 97% sensi

34 Only one infant required ligation of a patent ductus arteriosus during ECMO.

35 an autosomal dominant trait characterized by patent ductus arteriosus, facial dysmorphism and hand an

36 association was observed between PM(10) and patent ductus arteriosus (for an interquartile range inc

37 Gentamicin clearance was decreased in the patent ductus arteriosus group vs. the control group (40

38 The infants with patent ductus arteriosus had higher values for ventricul

39 Although transcatheter coil occlusion of patent ductus arteriosus has gained popularity, few foll

40 acin for the prevention and treatment of the patent ductus arteriosus have not documented a decrease

41 beta, a transcription factor associated with patent ductus arteriosus in humans, was uniquely express

42 sulted in cardiopulmonary defects, including patent ductus arteriosus, in 30 to 40% of the mice.

43 In the preterm newborn, a patent ductus arteriosus is in large part a result of th

44 Patent ductus arteriosus ligation among preterm neonates

45 Since the first patent ductus arteriosus ligation by Robert Gross of Bos

46 All 14 premature infants undergoing patent ductus arteriosus ligation in a 1-year period at

47 lar resistance associated with ligation of a patent ductus arteriosus might worsen ventricular perfor

48 322 courses of gentamicin were administered (patent ductus arteriosus, n = 106; control, n = 216).

49 Patent ductus arteriosus occlusion can be accomplished b

50 children with secundum atrial septal defect, patent ductus arteriosus, or pulmonic stenosis have had

51 Volume of distribution was greater for patent ductus arteriosus patients (0.61 L/kg) than for c

52 results of buttoned device (BD) occlusion of patent ductus arteriosus (PDA) in a large number of pati

53 consensus for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infa

54 Patent ductus arteriosus (PDA) is a common congenital he

55 Nonsyndromic patent ductus arteriosus (PDA) is a common congenital he

56 Patent ductus arteriosus (PDA) is a relatively common fo

57 Patent ductus arteriosus (PDA) is associated with increa

58 Observational studies have associated patent ductus arteriosus (PDA) ligation among preterm in

59 Patent ductus arteriosus (PDA) poses a diagnostic and th

60 was performed to determine the frequency of patent ductus arteriosus (PDA) reopening and the factors

61 od flow may undergo palliation with either a patent ductus arteriosus (PDA) stent or a modified Blalo

62 Transcatheter closure of a moderate to large patent ductus arteriosus (PDA) using conventional techni

63 The patent ductus arteriosus (PDA) was the first congenital

64 Only one atrial septal defect (ASD) and two patent ductus arteriosus (PDA) were missed by DSCT.

65 We found that patent ductus arteriosus (PDA), a common congenital hear

66 ve (BAV), coarctation of the aorta (CoA) and patent ductus arteriosus (PDA).

67 uding aneurysmal dilatation of the aorta and patent ductus arteriosus (PDA).

68 irth, but died prior to postnatal day 3 from patent ductus arteriosus (PDA).

69 ding a locus at 16p for TAAD associated with patent ductus arteriosus (PDA).

70 e to coil occlude the moderate to large size patent ductus arteriosus (PDA).

71 fants receiving indomethacin (INDO) to close patent ductus arteriosus (PDA).

72 trial septal defect (ASD); device closure of patent ductus arteriosus (PDA); pulmonary valvuloplasty;

73 es the use of Gianturco coils to close large patent ductus arteriosus (PDAs) (> or = 3.5 mm) and desc

74 ricular and atrioventricular septal defects; patent ductus arteriosus; pulmonary stenosis; aortic ste

75 tricular leukomalacia, chronic lung disease, patent ductus arteriosus requiring surgery, retinopathy

76 Although a persistent patent ductus arteriosus results in diminished cardiac f

77 atrial septal defects, patent foramen ovale, patent ductus arteriosus, stent placement for pulmonary

78 in dosing should be altered in neonates with patent ductus arteriosus to reflect the impact of higher

79 oarctation, hypoplastic left heart syndrome, patent ductus arteriosus, valvar pulmonary stenosis, tet

80 treated cases regardless of whether preterm patent ductus arteriosus was included.

81 f infants who required surgical closure of a patent ductus arteriosus was lower in the budesonide gro

82 ory of asthma, smoking in the household, and patent ductus arteriosus were predictive of wheezing in

83 cts, persistent left superior vena cava, and patent ductus arteriosus, were present in 32% of patient

84 e development of better therapy to close the patent ductus arteriosus, which constitutes approximatel

85 Necropsy revealed patent ductus arteriosus with normal intimal thickening

86 ribution was a useful marker for presence of patent ductus arteriosus, with a 92% specificity for pat